Provided by Tiger Trade Technology Pte. Ltd.

Celcuity Inc

65.78
-5.4700-7.68%
Pre-market: 65.40-0.3800-0.58%07:58 EDT
Volume:3.16M
Turnover:212.54M
Market Cap:3.21B
PE:-15.22
High:73.51
Open:70.52
Low:64.15
Close:71.25
52wk High:151.02
52wk Low:45.03
Shares:48.77M
Float Shares:29.72M
Volume Ratio:1.89
T/O Rate:10.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3223
EPS(LYR):-3.7900
ROE:-1433.70%
ROA:-25.78%
PB:-250.99
PE(LYR):-17.36

Loading ...

Celcuity Files Form 3 Initial Beneficial Ownership Statement for Director David W. Gryska

Reuters
·
Oct 06

Celcuity to Present Updated Phase 3 Viktoria-1 Gedatolisib Data in Hr+/her2- Advanced Breast Cancer at ESMO 2026

Reuters
·
Oct 05

How REVTORPYK Launch Will Impact Celcuity (CELC) Investors

Simply Wall St.
·
Oct 03

Celcuity Appoints Ex-Incyte CFO David Gryska to Board

Reuters
·
Oct 02

Press Release: Celcuity Appoints David Gryska to Its Board of Directors

Dow Jones
·
Oct 02

Celcuity (CELC) Gets a Buy from H.C. Wainwright

TIPRANKS
·
Oct 01

Celcuity Price Target Cut to $134.00/Share from $140.00 by Needham

Dow Jones
·
Sep 30

Celcuity Inc. : Leerink Partners Cuts Target Price to $147.00 from $148.00

THOMSON REUTERS
·
Sep 30

Celcuity Gains as Breast Cancer Drug Launches in US

Reuters
·
Sep 30

Celcuity - Announces Revtorpyk NOW Commercially Available in the United States

THOMSON REUTERS
·
Sep 30

Celcuity Gains; J.P.Morgan Initiates Coverage with 'overweight'

Reuters
·
Sep 17

U.S. Research Roundup-Celcuity, Fluence Energy, Salesforce

Reuters
·
Sep 17

County Leader Inspects Progress on Key Construction Initiatives

Deep News
·
Sep 10

Celcuity submits Revtorpyk sNDA to the FDA

TIPRANKS
·
Aug 26

Celcuity Submits FDA sNDA for Revtorpyk in Pik3ca-Mutant Advanced Breast Cancer

Reuters
·
Aug 26

Celcuity Submits Snda to FDA for Revtorpyk™ (Gedatolisib) for Hr+/Her2-, Pik3CA Mutant Locally Advanced or Metastatic Breast Cancer

THOMSON REUTERS
·
Aug 26

Craig-Hallum Sticks to Its Buy Rating for Celcuity (CELC)

TIPRANKS
·
Aug 18

Celcuity Price Target Maintained with a $177.00/Share by Citizens

Dow Jones
·
Aug 17

Celcuity price target raised to $175 from $165 at Guggenheim

TIPRANKS
·
Aug 17

The Bull Case For Celcuity (CELC) Could Change Following Revtopik’s FDA Approval And NCCN Category 1 Status

Simply Wall St.
·
Aug 16